title: Hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation: incidence, risk factors, and outcome.
abstract: Four hundred and sixty-seven hematopoietic stem cell transplantations (HSCTs) (217 autologous and 250 allogeneic HSCT) were performed in 374 children at four pediatric HSCT centers in Korea from January 2005 to December 2007. Among 467 transplants, veno-occlusive disease (VOD) developed in 72 transplants (15.4%) at a median of 10 days after HSCT. Multivariate analysis showed that BU or TBI-containing regimen (P=0.002), VOD prophylaxis without lipo-prostaglandin E1 (PGE1) (P=0.012), number of previous HSCT (P=0.014), and pretransplant serum ferritin (P=0.018) were independent risk factors for developing VOD. Mean serum ferritin levels were significantly higher in HSCT with VOD (2109.6+/-2842.5 ng/ml) than in HSCT without VOD (1315.9+/-1094.4 ng/ml) (P<0.001). The relative risk of death within 100 days of HSCT in transplants with VOD compared with transplants without VOD was 3.39 (confidence interval: 1.78-6.45). Our results suggest that lipo-PGE1 might have a protective effect against the development of VOD, and pretransplant serum ferritin could act as a risk factor for VOD. A larger prospective study is needed to confirm a possible role of lipo-PGE1 and iron chelation therapy in reducing the incidence of VOD.
authors.affiliation: Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
authors.forename: S H
authors.initials: SH
authors.lastname: Lee
authors.forename: K H
authors.initials: KH
authors.lastname: Yoo
authors.forename: K W
authors.initials: KW
authors.lastname: Sung
authors.forename: H H
authors.initials: HH
authors.lastname: Koo
authors.forename: Y J
authors.initials: YJ
authors.lastname: Kwon
authors.forename: M M
authors.initials: MM
authors.lastname: Kwon
authors.forename: H J
authors.initials: HJ
authors.lastname: Park
authors.forename: B-K
authors.initials: BK
authors.lastname: Park
authors.forename: Y Y
authors.initials: YY
authors.lastname: Kim
authors.forename: J A
authors.initials: JA
authors.lastname: Park
authors.forename: H J
authors.initials: HJ
authors.lastname: Im
authors.forename: J J
authors.initials: JJ
authors.lastname: Seo
authors.forename: H J
authors.initials: HJ
authors.lastname: Kang
authors.forename: H Y
authors.initials: HY
authors.lastname: Shin
authors.forename: H S
authors.initials: HS
authors.lastname: Ahn
mesh_terms: D000527:Alprostadil / Q000627:therapeutic use; D002648:Child; D005260:Female; D005293:Ferritins / Q000097:blood; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006504:Hepatic Veno-Occlusive Disease / Q000453:epidemiology* / Q000209:etiology; D006801:Humans; D015994:Incidence; D007502:Iron Chelating Agents / Q000627:therapeutic use; D007723:Korea; D008297:Male; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome; D014665:Vasodilator Agents
chemical_list: D007502:Iron Chelating Agents; D014665:Vasodilator Agents; D005293:Ferritins; D000527:Alprostadil